Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Treatment of immune-mediated inflammatory diseases

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20201105001
Publicado:
09/11/2020
Caducidad:
10/11/2021
Resumen:
A German university offers a new compound to improve treatment of immune-mediated inflammatory diseases. It is based on a specific NMDAr (N-Methyl-D-Aspartat receptor) antagonist that selectively binds to the subunit NR2B and shows significant anti-inflammatory effect. Treatment with the new NR2B selective compound showed a less severe progression of multiple sclerosis in an in-vivo mouse model. The university offers license agreements to the therapeutic industry.

Details

Tittle:
Treatment of immune-mediated inflammatory diseases
Summary:
A German university offers a new compound to improve treatment of immune-mediated inflammatory diseases. It is based on a specific NMDAr (N-Methyl-D-Aspartat receptor) antagonist that selectively binds to the subunit NR2B and shows significant anti-inflammatory effect. Treatment with the new NR2B selective compound showed a less severe progression of multiple sclerosis in an in-vivo mouse model. The university offers license agreements to the therapeutic industry.
Description:
Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and highly disabling diseases that share common inflammatory pathways. Despite an increasing therapeutic armamentarium, there is still an urgent need for novel and improved therapeutic approaches for treating immune-mediated inflammatory diseases, such as multiple sclerosis, preferably exhibiting fewer adverse side effects and an improved clinical efficacy.

NMDAr (N-Methyl-D-Aspartat receptors) are glutamate-gated ion channels reported to be widely expressed in the central nervous system. NMDArs have hence triggered an intense interest as potential therapeutic drug targets. However, their intended use has been classically restricted to treatment of diseases affecting the central nervous systems associated with neuronal dysfunction or glutamate excitotoxicity. Several NMDAr antagonists were developed, including uncompetitive NMDAr antagonists binding to the NMDA ion channel and competitive antagonists acting at the agonist-binding domain on the NR2 subunits.

A German university recently developed novel improved NMDA-receptor antagonists specifically binding to the NR2B subunit of the receptor with high affinity. They found that immune cells (microglia and mono-cytes/dendritic cells), involved in the pathogenesis of IMIDs such as multiple sclerosis, express the NMDA receptor. Specifically, they upregulate the NR2B subunit under inflammatory conditions. Targeting the NR2B subunit of the NMDA receptor on microglia and monocytes resulted in a marked downregulation of activation markers and cytokine expression and/or secretion. The finding was confirmed in an in vivo mouse model of multiple sclerosis (experimental autoimmune encephalomyelitis; EAE), showing a markedly less severe progression of disease after treatment with the novel NR2B-selective compound, even if treatment was begun after symptoms had developed.

Industrial partners from therapeutic industry are sought for license agreements to produce and sell the invention.
Advantages and Innovations:
The newly developed specific NMDAr antagonist binds selectively to the NR2B subunit and shows an increased selectivity and specificity compared to known inhibitors.

Under normal conditions, NR2B is only expressed in specific brain regions. Under auto-inflammatory conditions, the university found a marked upregulation of NR2B on microglia and myeloid cells. Blockade of NR2B showed a significant anti-inflammatory effect both in vitro and in an animal model of multiple sclerosis.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applications have been filed in Europe and the USA.

Partner sought

Type and Role of Partner Sought:
Partners sought are providers of therapeutic products.

The university offers license agreements. Within this framework the partner should produce and sell the new development

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos